Filtered By:
Drug: Coumadin
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 3661 results found since Jan 2013.
Direct Oral Anticoagulants Versus Vitamin K Antagonist (Warfarin) For Stroke Prevention In Frail Patients With Atrial Fibrillation: A Meta-Analysis
Proc (Bayl Univ Med Cent). 2022 Dec 22;36(2):274-275. doi: 10.1080/08998280.2022.2155926. eCollection 2023.NO ABSTRACTPMID:36876251 | PMC:PMC9980567 | DOI:10.1080/08998280.2022.2155926
Source: Baylor University Medical Center Proceedings - March 6, 2023 Category: Universities & Medical Training Authors: Rupak Desai Aobo Li Avilash Mondal Priya Shenwai Bhavyasri Merugu Frailyn J Nunez Guzman Akhil Jain Source Type: research
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
The importance of time in therapeutic range of warfarin for stroke prevention in atrial fibrillation
Kardiol Pol. 2023;81(2):105-106. doi: 10.33963/KP.a2023.0050.NO ABSTRACTPMID:36866399 | DOI:10.33963/KP.a2023.0050
Source: Kardiologia Polska - March 3, 2023 Category: Cardiology Authors: Tze-Fan Chao Chih-Min Liu Jo-Nan Liao Source Type: research
Drug-drug interactions with direct oral anticoagulants for the prevention of ischemic stroke and embolism in atrial fibrillation: a narrative review of adverse events
Expert Rev Clin Pharmacol. 2023 Mar 2. doi: 10.1080/17512433.2023.2187376. Online ahead of print.ABSTRACTINTRODUCTION: In randomized trials, direct oral anticoagulants (DOAC) were non-inferior to the vitamin-K-antagonist (VKA) warfarin in preventing stroke/embolism in patients with atrial fibrillation (AF). DOAC are substrates for P-glycoprotein (P-gp), CYP3A4 and CYP2C9. The activity of these enzymes is modulated by several drugs which might induce pharmacokinetic drug-drug interactions (DDI). Drugs affecting platelet function have the potential for pharmacodynamic DDI of DOAC.AREAS COVERED: The literature was searched fo...
Source: Pharmacological Reviews - March 2, 2023 Category: Drugs & Pharmacology Authors: Claudia St öllberger Birke Schneider Josef Finsterer Source Type: research
